Bristol Glucophage Price Increase Highlighted In Families USA Report
Bristol-Myers Squibb's efforts to price its diabetes therapy Glucophage to reflect its "best in class" status have drawn the attention of Families USA and Congressional Democrats.
Bristol-Myers Squibb's efforts to price its diabetes therapy Glucophage to reflect its "best in class" status have drawn the attention of Families USA and Congressional Democrats.